Quinten Health participated in the 10th International Meeting on Statistical Methods in Biopharmacy (SnB2025), held in Paris from October 8 to 10, 2025.
Representation
Quinten Health was represented by Sonia Zebachi, Alexandre Macquin and Ce Jiang, who shared the company’s vision and expertise at booth #12.
Their presence reflected Quinten Health’s ongoing engagement in promoting rigorous, data-driven approaches to decision-making across the healthcare and biopharmaceutical sectors.
Scientific Contribution
During the conference, Ce Jiang presented a scientific poster entitled:
“Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials in Drug Development from a Multi-Stakeholder Perspective: A Scoping Review.”
This work explores the diversity of perspectives and methodological approaches used by stakeholders when deciding to initiate late-stage clinical trials, contributing to the understanding of how evidence-based frameworks can improve decision quality in drug development.
This research has been conducted as part of the Work package 1 in the More-EUROPA consortium, which aims to develop, implement and establish evidentiary standards and methods to address the data and evidentiary needs of regulatory authorities and HTA bodies towards a more efficient use of RWD for the development, registration and assessment of medicinal products in Europe.
Commitment to Scientific Dialogue and Innovation
Participation in SnB2025 illustrates Quinten Health’s commitment to advancing the integration of statistical methods, data science, and real-world evidence into the design and evaluation of clinical research.
Through continuous collaboration with the scientific community, Quinten Health supports the development of transparent, reproducible, and efficient methodologies that enhance the reliability of clinical and regulatory decision-making.
About SnB2025
The 10th International Meeting on Statistical Methods in Biopharmacy (SnB2025) is organized by the Statistics and Biopharmacy group of the SFdS (French Society of Statistics).
Held in Paris from October 8 to 10, 2025, the event brings together experts from academia, regulatory agencies, and the pharmaceutical industry to discuss innovative statistical methods supporting drug development.
This year’s edition focuses on advancing drug development through innovative designs and efficient data use, covering topics such as Bayesian methods, causal inference, and the integration of real-world data in biostatistical practice.
